Table 1 Anthropometric and clinical measures of the cohort.
From: The DECON pilot project investigates predictive markers for successful bariatric surgery
Overall (N = 50) | |
|---|---|
Age, years | 37.38 ± 7.51 |
BMI, kg/m2 | 46.47 ± 5.93 |
WHO obesity classification, N (%) | |
Class II (BMI 35—39.9 kg/m2) | 3 (6%) |
Class III (BMI ≥ 40 kg/m2) | 47 (94%) |
WHR | 0.88 ± 0.12 |
WHtR | 0.76 ± 0.07 |
Mid-thigh circumference, cm | 72.24 ± 8.26 |
HbA1c, % | 5.73 ± 1.08 |
HOMA IR, % | 1.64 ± 1.14 |
HOMA B, % | 90.26 ± 53.63 |
Triglycerides, mg/dL | 136.80 ± 181.23 |
Triglyceride level, N (%) | |
Normal (< 150 mg/dL) | 36 (72%) |
Borderline (150—199 mg/dL) | 6 (12%) |
High (≥ 200 mg/dL) | 2 (4%) |
Total cholesterol, mg/dL | 176.50 ± 32.26 |
HDL, mg/dL | 51.32 ± 21.67 |
HDL level, N (%) | |
Low (< 40 mg/dL) | 12 (24%) |
Reduced (40—59 mg/dL) | 9 (18%) |
Normal (≥ 60 mg/dL) | 23 (46%) |
LDL, mg/dL | 118.95 ± 33.79 |
LDL level, N (%) | |
Normal (< 130 mg/dL) | 26 (52%) |
Borderline (130—159 mg/dL) | 16 (32%) |
High (≥ 160 mg/dL) | 2 (4%) |
ALT, U/L | 35.04 ± 24.18 |
ALT level, N (%) | |
Normal (< 33 U/L) | 32 (64%) |
High (≥ 33 U/L) | 18 (36%) |
AST, U/L | 27.02 ± 14.32 |
AST level, N (%) | |
Normal (< 40 U/L) | 47 (94%) |
High (≥ 40 U/L) | 3 (6%) |
Uric Acid, mg/dL | 5.61 ± 1.14 |
Uric acid level, (%) | |
Normal (< 6 mg/dL) | 26 (52%) |
High (≥ 6 mg/dL) | 18 (36%) |
C-reactive protein, mg/L | 7.18 ± 6.59 |
C-reactive protein level, N (%) | |
Normal | 7 (14%) |
High | 42 (84%) |
Edmonton obesity stage, N (%) | |
0 | 5 (10%) |
1 | 17 (34%) |
2 | 23 (46%) |
3 | 5 (10%) |
4 | 0 (0%) |
Surgery type, N (%) | |
Sleeve gastrectomy | 13 (26%) |
Banded sleeve gastrectomy | 2 (4%) |
Roux-en-Y Gastric bypass | 23 (46%) |
Banded Roux-en-Y Gastric bypass | 12 (24%) |
